{'fraction_non_alphanumeric': 0.03142857142857143, 'fraction_numerical': 0.010476190476190476, 'mean_word_length': 5.331325301204819, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Safety evaluation of micronomicin. II. Irritation by repeated intravenous injection in dogs].

Micronomicin (MCR) is a new aminoglycoside antibiotic produced by Micromonospora sagamiensis var. nonreducans which was isolated from soil collected at Sagamihara by Nara et al. The purified antibiotic showed a close similarity to gentamicin C complex in physical and chemical properties. The antibacterial activity of MCR is broad-spectrum and almost equal to that of gentamicin C complex. MCR exhibits particularly high activity against Pseudomonas, Proteus, Klebsiella pneumoniae, Serratia, etc. and high activity against some Pseudomonas aeruginosa strains resistant to gentamicin C1a. A study on the irritation by repeated intravenous injection in dogs was carried out for safety evaluation (Doses: 4, 10, 25, 63 mg/kg and 100 mg/kg). Bleeding, edema, vasculitis and perivasculitis were observed at injection sites both in physiological saline-treated controls and MCR-treated groups. But irritation attributable to MCR was not observed at any dose.